Thermo Fisher Scientific Human IL-29 (IFN lambda-1) (ELISA Standard) Recombinant Protein, eBioscience

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-Dependent

-

Control (Ctrl)

Assay-Dependent

-

Product Specifications

Expression System

E. coli

Class

Recombinant

Type

Protein

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Storage conditions

-80°C

Product Specific Information

Description: IFN-lambdas are a novel family of interferons which mediate the induction of anti-viral protection in a wide variety of cells. The three members of the IFN-lambda family are lambda1, lambda2, and lambda3, also known as IL-29, IL-28A, and IL-28B, respectively. IFN-lambdas share with type I IFNs an intracellular signaling pathway that drives the expression of a common set of IFN-stimulated genes. IFN-lambdas induce multiple biological activities, including the upregulation of class I MHC gene product expression to levels comparable to those induced by IFN-alphas. IL-28 and IL-29 are tested for anti-viral activity by challenging the human hepatocellular carcinoma cell line HepG2 with infection by EMC (following pretreatment of the cells with cytokine).

Consistent with a role in anti-viral protection, the mRNA expression of IFN-lambdas is detectable in cells infected with various viruses. Moreover, monocyte-derived dendritic cells (important producers of IFN-alpha) express IFN-lambda1 mRNA in response to treatment with dsRNA. TLR3 and TLR4 ligands induce IFN-alpha, IFN-beta, IL-28, and IL-29 gene expression in macrophages; this is dependent upon IFN-alpha.

IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex distinct from that of type I IFNs. This is comprised of two essential receptor proteins, CRF2-12/IFN-lambdaR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. Whereas, the two chains of the type I IFN receptor (IFN-AR1 and IFN-AR2) and IL-10R2 are ubiquitously expressed, IFN-lambdaR1 expression is limited and cell-type dependent. IFN-lambdaR1 is not expressed by monocytes, but is up-regulated during GM-CSF/IL-4 induced differentiation of DCs from human monocytes, yielding iDCs which are fully responsive to IFN-lambda.

The IFN-lambdas, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. IFN-lambda-matured DCs express high levels of class I and II MHC gene products, but low levels of costimulatory molecules, and are able to specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cell population with contact dependent suppressive activity on T cells.

Applications Reported: Recombinant human IL-29 is biologically active. The intended use of the Recombinant Human IL-29 Single-Use ELISA RSG Standard is as a standard for human IL-29 Ready-SET-Go! ELISA and human IL-29 matched antibody pair ELISA. Typically the standard is run in a series of 7 doubling dilutions from the top standard described below.

Instructions for use: For Ready-SET-Go! ELISA Set (TMB substrate). Dilution: Add 10 µL of standard solution to 10 mL of assay diluent to prepare the top standard solution (1000 pg/mL).For matched antibody pair ELISA (ABTS or Super AquaBlue substrate). Dilution: Add 10 µL of standard solution to 10 mL of assay diluent to prepare the top standard solution (1000 pg/mL).

Note: These are single-use vials. Use one time and discard. Dilute as suggested above, not difficult-to-measure fractions of the suggested volumes (e.g., not 0.5 µL in 1.0 mL) or recovery may not be accurate. Use within 6 hours of dilution to top standard concentration.

Applications Tested: This cytokine standard has been calibrated, and subsequently tested by sandwich ELISA using the human IL-29 ELISA pair.

Source: E. coli expressed amino acids gly 20-thr 200 of mature human IL-29 accession # NM_172140.

Purity: >98% as determined by SDS-PAGE.

Storage and handling: For best recovery, quick-spin vial prior to opening. For dilution of current stock, use ELISA Assay Diluent.

Target Information

IFN-lambdas constitute a novel family of interferons that mediate the induction of anti-viral protection in a wide variety of cells. There are three members in this family, namely lambda1, lambda2, and lambda3, which are also known as IL-29, IL-28A, and IL-28B, respectively. Similar to type I IFNs, IFN-lambdas activate an intracellular signaling to promote gene expression. IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex composed of two essential receptor proteins, CRF2-12/IFN-lambdaR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. The IFN-lambdas, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. DCs that differentiate in response to IFN-lambdas express high levels of class I and II MHC gene products, but low levels of costimulatory molecules. Moreover, these cells can specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cells with contact-dependent suppressive activity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.